{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T21:57:54Z","timestamp":1790114274994,"version":"4.0.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":37,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U54CA224081"],"award-info":[{"award-number":["U54CA224081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA217882"],"award-info":[{"award-number":["U01CA217882"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA204302"],"award-info":[{"award-number":["R01CA204302"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA211052"],"award-info":[{"award-number":["R01CA211052"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Kinnate Biopharma Chan-Zuckerberg Biohub"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncogenic BRAF mutations, including those in non-small cell lung cancer (NSCLC), are classified as Class I, II, or III. While approved therapies exist for BRAF Class I mutants, no approved therapies exist for Class II and III BRAF-mutated NSCLC. Analysis of a circulating tumor DNA database reveals Class II and III mutations comprise ~65% of BRAF-mutant NSCLC cases, with Class II patients showing worse outcomes than Class I. Exarafenib, a distinct pan-RAF inhibitor, demonstrates potent activity against BRAF Class II and III mutant preclinical models and initial clinical activity. Resistance studies reveal rewiring to an ARAF-mediated bypass pathway, characterized by RAS-mediated ARAF-KSR1 complexes maintaining MAPK signaling despite pan-RAF inhibitor treatment. RAS or MEK inhibition co-targeting is effective against this resistance mechanism. This study provides preclinical rationale for clinical testing of exarafenib in BRAF Class II\/III cancers and unveils RAS-mediated ARAF-KSR1 complex formation as a resistance mechanism and rational co-therapy strategies.<\/jats:p>","DOI":"10.1038\/s41467-026-69216-3","type":"journal-article","created":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T16:35:34Z","timestamp":1770482134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pan-RAF inhibitor exarafenib targets BRAF class II\/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-5222","authenticated-orcid":false,"given":"Tadashi","family":"Manabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1879-0791","authenticated-orcid":false,"given":"Hannah C.","family":"Bergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingtian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim Sen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6762-6557","authenticated-orcid":false,"given":"Paul","family":"Severson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichol","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3105-3557","authenticated-orcid":false,"given":"Catherine","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elifnur","family":"Yay Donderici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2706-5838","authenticated-orcid":false,"given":"Nicole","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-067X","authenticated-orcid":false,"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ting","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Allegakoen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6917-0372","authenticated-orcid":false,"given":"Kathryn B.","family":"Grandinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Soroceanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Pelham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3119-9334","authenticated-orcid":false,"given":"Joel W.","family":"Neal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1193-1815","authenticated-orcid":false,"given":"Shumei","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5734-4128","authenticated-orcid":false,"given":"Trever G.","family":"Bivona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,7]]},"reference":[{"key":"69216_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/nrm3979","volume":"16","author":"H Lavoie","year":"2015","unstructured":"Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 16, 281\u2013298 (2015).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"69216_CR2","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega, F. et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173, 321\u2013337.e310 (2018).","journal-title":"Cell"},{"key":"69216_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1535370220959657","volume":"246","author":"J Owsley","year":"2021","unstructured":"Owsley, J. et al. Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp. Biol. Med. 246, 31\u201339 (2021).","journal-title":"Exp. Biol. Med."},{"key":"69216_CR4","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao, Z. et al. BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28, 370\u2013383 (2015).","journal-title":"Cancer Cell"},{"key":"69216_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao, Z. et al. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548, 234\u2013238 (2017).","journal-title":"Nature"},{"key":"69216_CR6","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard, D. et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 17, 984\u2013993 (2016).","journal-title":"Lancet Oncol."},{"key":"69216_CR7","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444\u2013451 (2015).","journal-title":"Lancet"},{"key":"69216_CR8","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"69216_CR9","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1634\/theoncologist.2016-0458","volume":"22","author":"CS Baik","year":"2017","unstructured":"Baik, C. S., Myall, N. J. & Wakelee, H. A. Targeting BRAF-mutant non-small cell lung cancer: from molecular profiling to rationally designed therapy. Oncologist 22, 786\u2013796 (2017).","journal-title":"Oncologist"},{"key":"69216_CR10","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"69216_CR11","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"69216_CR12","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","volume":"25","author":"I Dagogo-Jack","year":"2019","unstructured":"Dagogo-Jack, I. et al. Impact of BRAF mutation class on disease characteristics and clinical outcomes in braf-mutant lung cancer. Clin. Cancer Res. 25, 158\u2013165 (2019).","journal-title":"Clin. Cancer Res."},{"key":"69216_CR13","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","volume":"19","author":"S Cardarella","year":"2013","unstructured":"Cardarella, S. et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin. Cancer Res. 19, 4532\u20134540 (2013).","journal-title":"Clin. Cancer Res."},{"key":"69216_CR14","doi-asserted-by":"publisher","first-page":"e398","DOI":"10.3747\/co.25.3945","volume":"25","author":"JB Auliac","year":"2018","unstructured":"Auliac, J. B. et al. Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14. Curr. Oncol. 25, e398\u2013e402 (2018).","journal-title":"Curr. Oncol."},{"key":"69216_CR15","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jtho.2023.07.024","volume":"18","author":"T Sakai","year":"2023","unstructured":"Sakai, T. et al. Clinicogenomic features and targetable mutations in NSCLCs harboring BRAF non-V600E mutations: a multi-institutional genomic screening study (LC-SCRUM-Asia). J. Thorac. Oncol. 18, 1538\u20131549 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"69216_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejca.2021.02.036","volume":"149","author":"M Wiesweg","year":"2021","unstructured":"Wiesweg, M. et al. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy. Eur. J. Cancer 149, 211\u2013221 (2021).","journal-title":"Eur. J. Cancer"},{"key":"69216_CR17","doi-asserted-by":"publisher","first-page":"3539","DOI":"10.1158\/1078-0432.CCR-17-3831","volume":"24","author":"JI Odegaard","year":"2018","unstructured":"Odegaard, J. I. et al. Validation of a plasma-based comprehensive cancer genotyping assay utilizing orthogonal tissue- and plasma-based methodologies. Clin. Cancer Res. 24, 3539\u20133549 (2018).","journal-title":"Clin. Cancer Res."},{"key":"69216_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer, E., Haque, I. S., Roberts, C. E. S. & Speicher, M. R. Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat. Rev. Genet. 20, 71\u201388 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"69216_CR19","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat. Rev. Cancer 17, 223\u2013238 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"69216_CR20","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1021\/acs.jmedchem.3c01830","volume":"67","author":"YK Chen","year":"2024","unstructured":"Chen, Y. K. et al. The discovery of exarafenib (KIN-2787): overcoming the challenges of pan-RAF kinase inhibition. J. Med. Chem. 67, 1747\u20131757 (2024).","journal-title":"J. Med. Chem."},{"key":"69216_CR21","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s41591-018-0274-5","volume":"25","author":"Z Yao","year":"2019","unstructured":"Yao, Z. et al. RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling. Nat. Med. 25, 284\u2013291 (2019).","journal-title":"Nat. Med."},{"key":"69216_CR22","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner, M., Rose, A. A. N., Rajkumar, S., Siegel, P. M. & Watson, I. R. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37, 3183\u20133199 (2018).","journal-title":"Oncogene"},{"key":"69216_CR23","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nature08902","volume":"464","author":"PI Poulikakos","year":"2010","unstructured":"Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427\u2013430 (2010).","journal-title":"Nature"},{"key":"69216_CR24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature08833","volume":"464","author":"G Hatzivassiliou","year":"2010","unstructured":"Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431\u2013435 (2010).","journal-title":"Nature"},{"key":"69216_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.ccell.2015.08.002","volume":"28","author":"SB Peng","year":"2015","unstructured":"Peng, S. B. et al. Inhibition of RAF isoforms and active dimers by LY3009120 leads to anti-tumor activities in RAS or BRAF mutant cancers. Cancer Cell 28, 384\u2013398 (2015).","journal-title":"Cancer Cell"},{"key":"69216_CR26","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1158\/1078-0432.CCR-20-2563","volume":"27","author":"KA Monaco","year":"2021","unstructured":"Monaco, K. A. et al. LXH254, a potent and selective ARAF-sparing inhibitor of BRAF and CRAF for the treatment of MAPK-driven tumors. Clin. Cancer Res. 27, 2061\u20132073 (2021).","journal-title":"Clin. Cancer Res."},{"key":"69216_CR27","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41586-021-03515-1","volume":"594","author":"I Yen","year":"2021","unstructured":"Yen, I. et al. ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma. Nature 594, 418\u2013423 (2021).","journal-title":"Nature"},{"key":"69216_CR28","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ccell.2016.08.008","volume":"30","author":"Z Karoulia","year":"2016","unstructured":"Karoulia, Z. et al. An integrated Model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling. Cancer Cell 30, 501\u2013503 (2016).","journal-title":"Cancer Cell"},{"key":"69216_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113458","volume":"196","author":"F Janku","year":"2024","unstructured":"Janku, F. et al. First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations. Eur. J. Cancer 196, 113458 (2024).","journal-title":"Eur. J. Cancer"},{"key":"69216_CR30","doi-asserted-by":"crossref","unstructured":"Kim, K. H. et al. Exploring molecular genetic alterations and RAF fusions in melanoma: a belvarafenib expanded access program in patients with RAS\/RAF-mutant melanoma. Oncologist 29, e811\u2013e821 (2024).","DOI":"10.1093\/oncolo\/oyae018"},{"key":"69216_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01274-0","volume":"8","author":"T Jin","year":"2017","unstructured":"Jin, T. et al. RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition. Nat. Commun. 8, 1211 (2017).","journal-title":"Nat. Commun."},{"key":"69216_CR32","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.cell.2015.04.045","volume":"161","author":"E Desideri","year":"2015","unstructured":"Desideri, E., Cavallo, A. L. & Baccarini, M. Alike but different: RAF paralogs and their signaling outputs. Cell 161, 967\u2013970 (2015).","journal-title":"Cell"},{"key":"69216_CR33","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/cas.15263","volume":"113","author":"T Koga","year":"2022","unstructured":"Koga, T., Suda, K. & Mitsudomi, T. Utility of the Ba\/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer. Cancer Sci. 113, 815\u2013827 (2022).","journal-title":"Cancer Sci."},{"key":"69216_CR34","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med"},{"key":"69216_CR35","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1038\/sj.onc.1205550","volume":"21","author":"AS Lundberg","year":"2002","unstructured":"Lundberg, A. S. et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 21, 4577\u20134586 (2002).","journal-title":"Oncogene"},{"key":"69216_CR36","doi-asserted-by":"publisher","first-page":"E748","DOI":"10.1073\/pnas.1320956111","volume":"111","author":"L Lin","year":"2014","unstructured":"Lin, L. et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc. Natl. Acad. Sci. USA 111, E748\u2013E757 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69216_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nature10662","volume":"480","author":"PI Poulikakos","year":"2011","unstructured":"Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387\u2013390 (2011).","journal-title":"Nature"},{"key":"69216_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.21037\/jgo.2019.01.10","volume":"10","author":"L Midthun","year":"2019","unstructured":"Midthun, L. et al. Concomitant KRAS and BRAF mutations in colorectal cancer. J. Gastrointest. Oncol. 10, 577\u2013581 (2019).","journal-title":"J. Gastrointest. Oncol."},{"key":"69216_CR39","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/j.cllc.2020.02.018","volume":"21","author":"A Bourhis","year":"2020","unstructured":"Bourhis, A., Remoue, A. & Uguen, A. KRAS and BRAF double mutations and functional classes of BRAF mutations in non-small-cell lung cancers. Clin. Lung Cancer 21, e240\u2013e242 (2020).","journal-title":"Clin. Lung Cancer"},{"key":"69216_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2036-7","volume":"17","author":"Q Lin","year":"2019","unstructured":"Lin, Q. et al. The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. J. Transl. Med. 17, 298 (2019).","journal-title":"J. Transl. Med."},{"key":"69216_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N. Engl. J. Med. 372, 30\u201339 (2015).","journal-title":"N. Engl. J. Med."},{"key":"69216_CR42","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin, J. et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med. 371, 1867\u20131876 (2014).","journal-title":"N. Engl. J. Med."},{"key":"69216_CR43","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s12094-022-02849-0","volume":"25","author":"I Tsamis","year":"2023","unstructured":"Tsamis, I. et al. BRAF\/MEK inhibition in NSCLC: mechanisms of resistance and how to overcome it. Clin. Transl. Oncol. 25, 10\u201320 (2023).","journal-title":"Clin. Transl. Oncol."},{"key":"69216_CR44","doi-asserted-by":"crossref","unstructured":"Zaman, A., Wu, W. & Bivona, T. G. Targeting oncogenic BRAF: past, present, and future. Cancers 11, 1197 (2019).","DOI":"10.3390\/cancers11081197"},{"key":"69216_CR45","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.tibs.2011.03.006","volume":"36","author":"MC Mendoza","year":"2011","unstructured":"Mendoza, M. C., Er, E. E. & Blenis, J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem. Sci. 36, 320\u2013328 (2011).","journal-title":"Trends Biochem. Sci."},{"key":"69216_CR46","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1158\/0008-5472.CAN-11-3747","volume":"72","author":"AB Turke","year":"2012","unstructured":"Turke, A. B. et al. MEK inhibition leads to PI3K\/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res. 72, 3228\u20133237 (2012).","journal-title":"Cancer Res."},{"key":"69216_CR47","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1158\/1541-7786.MCR-18-0327","volume":"17","author":"GP Leung","year":"2019","unstructured":"Leung, G. P. et al. Hyperactivation of MAPK signaling is deleterious to RAS\/RAF-mutant Melanoma. Mol. Cancer Res. 17, 199\u2013211 (2019).","journal-title":"Mol. Cancer Res."},{"key":"69216_CR48","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","volume":"27","author":"G Moriceau","year":"2015","unstructured":"Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240\u2013256 (2015).","journal-title":"Cancer Cell"},{"key":"69216_CR49","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S0076-6879(05)07012-6","volume":"407","author":"TG Bivona","year":"2006","unstructured":"Bivona, T. G., Quatela, S. & Philips, M. R. Analysis of Ras activation in living cells with GFP-RBD. Methods Enzymol. 407, 128\u2013143 (2006).","journal-title":"Methods Enzymol."},{"key":"69216_CR50","doi-asserted-by":"publisher","first-page":"13456","DOI":"10.1073\/pnas.1610456113","volume":"113","author":"RA Okimoto","year":"2016","unstructured":"Okimoto, R. A. et al. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. Proc. Natl. Acad. Sci. USA 113, 13456\u201313461 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69216_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1158\/2159-8290.CD-11-0341","volume":"2","author":"RB Corcoran","year":"2012","unstructured":"Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227\u2013235 (2012).","journal-title":"Cancer Discov."},{"key":"69216_CR52","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","volume":"22","author":"P Lito","year":"2012","unstructured":"Lito, P. et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell 22, 668\u2013682 (2012).","journal-title":"Cancer Cell"},{"key":"69216_CR53","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.2004652","volume":"6","author":"MJ Niederst","year":"2013","unstructured":"Niederst, M. J. & Engelman, J. A. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer. Sci. Signal. 6, re6 (2013).","journal-title":"Sci. Signal."},{"key":"69216_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110351","volume":"38","author":"A Venkatanarayan","year":"2022","unstructured":"Venkatanarayan, A. et al. CRAF dimerization with ARAF regulates KRAS-driven tumor growth. Cell Rep. 38, 110351 (2022).","journal-title":"Cell Rep."},{"key":"69216_CR55","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.chembiol.2023.07.019","volume":"30","author":"JD Vasta","year":"2023","unstructured":"Vasta, J. D. et al. Protomer selectivity of type II RAF inhibitors within the RAS\/RAF complex. Cell Chem. Biol. 30, 1354\u20131365 e1356 (2023).","journal-title":"Cell Chem. Biol."},{"key":"69216_CR56","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1038\/nrm1743","volume":"6","author":"W Kolch","year":"2005","unstructured":"Kolch, W. Coordinating ERK\/MAPK signalling through scaffolds and inhibitors. Nat. Rev. Mol. Cell Biol. 6, 827\u2013837 (2005).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"69216_CR57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2313137120","volume":"120","author":"BR Daley","year":"2023","unstructured":"Daley, B. R. et al. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status. Proc. Natl. Acad. Sci. USA 120, e2313137120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69216_CR58","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.cub.2011.02.033","volume":"21","author":"MM McKay","year":"2011","unstructured":"McKay, M. M., Ritt, D. A. & Morrison, D. K. RAF inhibitor-induced KSR1\/B-RAF binding and its effects on ERK cascade signaling. Curr. Biol. 21, 563\u2013568 (2011).","journal-title":"Curr. Biol."},{"key":"69216_CR59","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84\u201387 (2013).","journal-title":"Science"},{"key":"69216_CR60","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","volume":"14","author":"J Jiang","year":"2024","unstructured":"Jiang, J. et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14, 994\u20131017 (2024).","journal-title":"Cancer Discov."},{"key":"69216_CR61","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41556-018-0169-1","volume":"20","author":"RJ Nichols","year":"2018","unstructured":"Nichols, R. J. et al. RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nat. Cell Biol. 20, 1064\u20131073 (2018).","journal-title":"Nat. Cell Biol."},{"key":"69216_CR62","doi-asserted-by":"publisher","first-page":"114073","DOI":"10.1016\/j.ejca.2024.114073","volume":"204","author":"D Schadendorf","year":"2024","unstructured":"Schadendorf, D. et al. COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E\/K-mutant melanoma. Eur. J. Cancer 204, 114073 (2024).","journal-title":"Eur. J. Cancer"},{"key":"69216_CR63","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(13)70024-X","volume":"14","author":"PA Ascierto","year":"2013","unstructured":"Ascierto, P. A. et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249\u2013256 (2013).","journal-title":"Lancet Oncol."},{"key":"69216_CR64","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1158\/1535-7163.MCT-19-0505","volume":"19","author":"AM Kidger","year":"2020","unstructured":"Kidger, A. M. et al. Dual-mechanism ERK1\/2 inhibitors exploit a distinct binding mode to block phosphorylation and nuclear accumulation of ERK1\/2. Mol. Cancer Ther. 19, 525\u2013539 (2020).","journal-title":"Mol. Cancer Ther."},{"key":"69216_CR65","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-20-0909","volume":"20","author":"JM Munck","year":"2021","unstructured":"Munck, J. M. et al. ASTX029, a novel dual-mechanism ERK inhibitor, modulates both the phosphorylation and catalytic activity of ERK. Mol. Cancer Ther. 20, 1757\u20131768 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"69216_CR66","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/1078-0432.CCR-12-3072","volume":"19","author":"J Lin","year":"2013","unstructured":"Lin, J. et al. Targeting activated Akt with GDC-0068, a novel selective Akt inhibitor that is efficacious in multiple tumor models. Clin. Cancer Res. 19, 1760\u20131772 (2013).","journal-title":"Clin. Cancer Res."},{"key":"69216_CR67","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1158\/2159-8290.CD-16-0512","volume":"7","author":"C Saura","year":"2017","unstructured":"Saura, C. et al. A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors. Cancer Discov. 7, 102\u2013113 (2017).","journal-title":"Cancer Discov."},{"key":"69216_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-018-0051-4","volume":"2","author":"MC Wagle","year":"2018","unstructured":"Wagle, M. C. et al. A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types. NPJ Precis Oncol. 2, 7 (2018).","journal-title":"NPJ Precis Oncol."},{"key":"69216_CR69","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/carcin\/bgq020","volume":"31","author":"Z Zhang","year":"2010","unstructured":"Zhang, Z. et al. Dual specificity phosphatase 6 (DUSP6) is an ETS-regulated negative feedback mediator of oncogenic ERK signaling in lung cancer cells. Carcinogenesis 31, 577\u2013586 (2010).","journal-title":"Carcinogenesis"},{"key":"69216_CR70","doi-asserted-by":"publisher","first-page":"2856","DOI":"10.1038\/sj.emboj.7601723","volume":"26","author":"KE Ewings","year":"2007","unstructured":"Ewings, K. E. et al. ERK1\/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 26, 2856\u20132867 (2007).","journal-title":"EMBO J."},{"key":"69216_CR71","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1038\/sj.onc.1207364","volume":"23","author":"M Marani","year":"2004","unstructured":"Marani, M. et al. Role of Bim in the survival pathway induced by Raf in epithelial cells. Oncogene 23, 2431\u20132441 (2004).","journal-title":"Oncogene"},{"key":"69216_CR72","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/bjc.2017.10","volume":"116","author":"JC Bendell","year":"2017","unstructured":"Bendell, J. C. et al. A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1\/2 inhibitor. Br. J. Cancer 116, 575\u2013583 (2017).","journal-title":"Br. J. Cancer"},{"key":"69216_CR73","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1158\/0008-5472.CAN-11-1515","volume":"72","author":"KP Hoeflich","year":"2012","unstructured":"Hoeflich, K. P. et al. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition. Cancer Res. 72, 210\u2013219 (2012).","journal-title":"Cancer Res."},{"key":"69216_CR74","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1158\/2159-8290.CD-13-0070","volume":"3","author":"EJ Morris","year":"2013","unstructured":"Morris, E. J. et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. Cancer Discov. 3, 742\u2013750 (2013).","journal-title":"Cancer Discov."},{"key":"69216_CR75","doi-asserted-by":"crossref","unstructured":"Sheikine, Y. et al. BRAF in lung cancers: analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations. JCO Precis. Oncol. 2, PO.17.00172 (2018).","DOI":"10.1200\/PO.17.00172"},{"key":"69216_CR76","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1158\/1078-0432.CCR-19-3563","volume":"26","author":"AJ Schoenfeld","year":"2020","unstructured":"Schoenfeld, A. J. et al. Tumor analyses reveal squamous transformation and off-target alterations as early resistance mechanisms to first-line osimertinib in EGFR-mutant lung cancer. Clin. Cancer Res. 26, 2654\u20132663 (2020).","journal-title":"Clin. Cancer Res."},{"key":"69216_CR77","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtho.2018.12.038","volume":"14","author":"M Vojnic","year":"2019","unstructured":"Vojnic, M. et al. Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J. Thorac. Oncol. 14, 802\u2013815 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"69216_CR78","doi-asserted-by":"publisher","first-page":"e226","DOI":"10.1016\/j.jtho.2019.05.046","volume":"14","author":"I Dagogo-Jack","year":"2019","unstructured":"Dagogo-Jack, I. et al. Response to the combination of osimertinib and trametinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF fusion. J. Thorac. Oncol. 14, e226\u2013e228 (2019).","journal-title":"J. Thorac. Oncol."},{"key":"69216_CR79","doi-asserted-by":"publisher","first-page":"e2500114","DOI":"10.1200\/OA-25-00114","volume":"3","author":"V Gambardella","year":"2026","unstructured":"Gambardella, V. et al. A phase 1 clinical trial evaluating safety, tolerability and early activity of exarafenib (KIN-2787), a highly selective pan-raf inhibitor, in BRAF\u2011altered solid tumors or NRAS-mutant Melanoma. JCO Oncol. Adv. 3, e2500114 (2026).","journal-title":"JCO Oncol. Adv."},{"key":"69216_CR80","doi-asserted-by":"publisher","first-page":"a001396","DOI":"10.1101\/mcs.a001396","volume":"3","author":"SJ Hsiao","year":"2017","unstructured":"Hsiao, S. J. et al. A novel, potentially targetable TMEM106B-BRAF fusion in pleomorphic xanthoastrocytoma. Cold Spring Harb. Mol. Case Stud. 3, a001396 (2017).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"69216_CR81","doi-asserted-by":"publisher","first-page":"S491","DOI":"10.1016\/j.annonc.2024.08.680","volume":"35","author":"P Cassier","year":"2024","unstructured":"Cassier, P. et al. 613MO A phase I clinical trial evaluating exarafenib, a selective pan-RAF inhibitor in combination with binimetinib in NRAS-mutant (NRASMut) melanoma (Mel) & BRAF-altered solid tumors. Ann. Oncol. 35, S491\u2013S492 (2024).","journal-title":"Ann. Oncol."},{"key":"69216_CR82","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-45","volume":"13","author":"J Thumar","year":"2014","unstructured":"Thumar, J., Shahbazian, D., Aziz, S. A., Jilaveanu, L. B. & Kluger, H. M. MEK targeting in N-RAS mutated metastatic melanoma. Mol. Cancer 13, 45 (2014).","journal-title":"Mol. Cancer"},{"key":"69216_CR83","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1093\/bioinformatics\/btw230","volume":"32","author":"GY Di Veroli","year":"2016","unstructured":"Di Veroli, G. Y. et al. Combenefit: an interactive platform for the analysis and visualization of drug combinations. Bioinformatics 32, 2866\u20132868 (2016).","journal-title":"Bioinformatics"},{"key":"69216_CR84","doi-asserted-by":"crossref","unstructured":"Di Federico, A. et al. Genomic landscape, clinical features and outcomes of non-small cell lung cancer patients harboring BRAF alterations of distinct functional classes. Cancers 14, 3472 (2022).","DOI":"10.3390\/cancers14143472"},{"key":"69216_CR85","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/nbt.2017","volume":"29","author":"T Anastassiadis","year":"2011","unstructured":"Anastassiadis, T., Deacon, S. W., Devarajan, K., Ma, H. & Peterson, J. R. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat. Biotechnol. 29, 1039\u20131045 (2011).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69216-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69216-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T03:03:00Z","timestamp":1773716580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69216-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69216"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69216-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5135027\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,7]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.G.B. is an advisor to Revolution Medicines, Relay, EcoR1, Engine, Novartis, Pfizer, Astrazeneca, Genentech, AbbVie, Daiichi Sankyo, and Granule Therapeutics, and receives research funding from Revolution Medicines, Verastem, and Nextpoint. J.W.N. reports stock ownership in SecondLook Health and receives royalties from UpToDate. He serves in a consulting or advisory role for AstraZeneca, Genentech\/Roche, Takeda Pharmaceuticals, Eli Lilly and Company, Amgen, Iovance Biotherapeutics, Blueprint Pharmaceuticals, Regeneron Pharmaceuticals, Natera, Gilead Sciences, AbbVie, Summit Therapeutics, Novartis, Novocure, Janssen Oncology, Anheart Therapeutics, Bristol-Myers Squibb, Nuvation Bio, Boehringer Ingelheim, Daiichi Sankyo, GlaxoSmithKline, Oxford BioTherapeutics, Taiho Pharmaceutical, Pfizer, and Foresight Diagnostics. He receives research funding (to self) from Revolution Medicines and Nuvalent, and research funding (to institution) from Genentech\/Roche, Merck, Novartis, Boehringer Ingelheim, Exelixis, Nektar Therapeutics, Takeda Pharmaceuticals, Adaptimmune, GSK, and Janssen. He has received honoraria from Research to Practice CME, Medscape CME, Projects in Knowledge CME, MJH Life Sciences CME, PlatformQ\/Medlive CME, IDEOlogy Health, Navya Network, Curio Science, and PER. C.T.C. receives grants from ADC Therapeutics, Bolt Biotherapeutics, D3 Bio, Genentech-Roche, Gilead Sciences, Kinnate Biopharma, Mersana, ORIC Pharmaceuticals, Palleon Pharmaceuticals, Pionyr Therapeutics, Rain Oncology, Revolution Medicines, Seagen, Tango Therapeutics, GSK, Eli Lilly, and Takeda and is a consultant or on advisory boards for Johnson & Johnson, Mubadala Capital, Tango Therapeutics, and Radionetics Oncology. S.K. serves as a consultant for Aadi Bioscience, Medpace, Foundation Medicine, NeoGenomics, and CureMatch. S.K. receives speaker\u2019s fees from Chugai, Roche\/Genentech, and Bayer, and serves on the advisory board for Pfizer. S.K. has research funding from ACT Genomics, Sysmex, Konica Minolta, OmniSeq, Personalis, and Function Oncology. T.S.W., P.S., N.M., C.L., K.B.G., L.S., R.J.P., E.S.M., and R.W. were full-time employees of Kinnate Biopharma at the time of the research. P.S. is an employee of Tupos Therapeutics and serves as a paid consultant for Pierre Fabre Laboratories. T.S.W. is an employee of Alterome Therapeutics. N.M. is an employee of Actio Biosciences. C.L. is an employee of Zentalis Pharmaceuticals. K.B.G. is a co-founder and employee of KymaThera Inc. L.S. is an employee of Fortvita Biologics. R.J.P. is an employee of Innovent Biologics. E.S.M. is an employee of Arpeggio Biosciences, Oncology New Co, and Storm Therapeutics. E.A.M. receives compensation, owns equity, has stock options, serves on the BOD, and is a co-founder of Alterome Therapeutics and Sidewinder Therapeutics. He serves as an advisor and has stock options in Architect Therapeutics, and previously received compensation, owned equity, had stock options, served on the BOD, and is a co-founder of Kinnate Biopharma. R.W. is an employee of Khora Therapeutics and serves as a paid consultant for Pierre Fabre Laboratories. E.D. and N.Z. are full-time employees and shareholders of Guardant Health. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2484"}}